434 related articles for article (PubMed ID: 6822737)
1. Neutralization of influenza virus by normal human sera: mechanisms involving antibody and complement.
Beebe DP; Schreiber RD; Cooper NR
J Immunol; 1983 Mar; 130(3):1317-22. PubMed ID: 6822737
[TBL] [Abstract][Full Text] [Related]
2. Neutralization of vesicular stomatitis virus (VSV) by human complement requires a natural IgM antibody present in human serum.
Beebe DP; Cooper NR
J Immunol; 1981 Apr; 126(4):1562-8. PubMed ID: 6259260
[TBL] [Abstract][Full Text] [Related]
3. Activation of the alternative complement pathway by EBV and the viral envelope glycoprotein, gp350.
Mold C; Bradt BM; Nemerow GR; Cooper NR
J Immunol; 1988 Jun; 140(11):3867-74. PubMed ID: 2836501
[TBL] [Abstract][Full Text] [Related]
4. Effect of selective complement deficiency on the rate of neutralization of enveloped viruses by human sera.
Leddy JP; Simons RL; Douglas RG
J Immunol; 1977 Jan; 118(1):28-34. PubMed ID: 187701
[TBL] [Abstract][Full Text] [Related]
5. Interactions of a nonneutralizing IgM antibody and complement in parainfluenza virus neutralization.
Vasantha S; Coelingh KL; Murphy BR; Dourmashkin RR; Hammer CH; Frank MM; Fries LF
Virology; 1988 Dec; 167(2):433-41. PubMed ID: 2849234
[TBL] [Abstract][Full Text] [Related]
6. Neutralization of Epstein-Barr virus by nonimmune human serum. Role of cross-reacting antibody to herpes simplex virus and complement.
Nemerow GR; Jensen FC; Cooper NR
J Clin Invest; 1982 Nov; 70(5):1081-91. PubMed ID: 6290536
[TBL] [Abstract][Full Text] [Related]
7. Antibody-independent neutralization of vesicular stomatitis virus by human complement. II. Formation of VSV-lipoprotein complexes in human serum and complement-dependent viral lysis.
Mills BJ; Beebe DP; Cooper NR
J Immunol; 1979 Dec; 123(6):2518-24. PubMed ID: 227957
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of C3 deposition on solid-phase bound immune complexes by lactoferrin.
Kievits F; Kijlstra A
Immunology; 1985 Mar; 54(3):449-56. PubMed ID: 3844370
[TBL] [Abstract][Full Text] [Related]
9. Possible mechanisms of the first step of the classical complement activation pathway: binding and activation of C1.
Füst G; Medgyesi GA; Rajnavölgyi E; Csécsi-Nagy M; Czikora K; Gergely J
Immunology; 1978 Dec; 35(6):873-84. PubMed ID: 104923
[TBL] [Abstract][Full Text] [Related]
10. Depressed classical complement pathway activities in chronic lymphocytic leukaemia.
Füst G; Czink E; Minh D; Miszlay Z; Varga L; Hollán SR
Clin Exp Immunol; 1985 Jun; 60(3):489-95. PubMed ID: 4017286
[TBL] [Abstract][Full Text] [Related]
11. The requirement of specific anticapsular IgG for killing of Haemophilus influenzae by the alternative pathway of complement activation.
Tarr PI; Hosea SW; Brown EJ; Schneerson R; Sutton A; Frank MM
J Immunol; 1982 Apr; 128(4):1772-5. PubMed ID: 6977569
[TBL] [Abstract][Full Text] [Related]
12. Staphylococcus aureus opsonization mediated via the classical and alternative complement pathways. A kinetic study using MgEGTA chelated serum and human sera deficient in IgG and complement factors C1s and C2.
Verbrugh HA; Van Dijk WC; Peters R; Van Der Tol ME; Peterson PK; Verhoef J
Immunology; 1979 Mar; 36(3):391-7. PubMed ID: 108204
[TBL] [Abstract][Full Text] [Related]
13. Prevention of immune precipitation by purified components of the alternative pathway.
Naama JK; Holme E; Hamilton E; Whaley K
Clin Exp Immunol; 1985 Apr; 60(1):169-77. PubMed ID: 3159522
[TBL] [Abstract][Full Text] [Related]
14. Studies of the mechanism of bacterial resistance to complement-mediated killing. V. IgG and F(ab')2 mediate killing of E. coli 0111B4 by the alternative complement pathway without increasing C5b-9 deposition.
Joiner KA; Goldman RC; Hammer CH; Leive L; Frank MM
J Immunol; 1983 Nov; 131(5):2563-9. PubMed ID: 6355296
[TBL] [Abstract][Full Text] [Related]
15. Effect of supraphysiologic levels of C1-inhibitor on the classical, lectin and alternative pathways of complement.
Nielsen EW; Waage C; Fure H; Brekke OL; Sfyroera G; Lambris JD; Mollnes TE
Mol Immunol; 2007 Mar; 44(8):1819-26. PubMed ID: 17101176
[TBL] [Abstract][Full Text] [Related]
16. C1- inactivator: its efficiency as a regulator of classical complement pathway activation by soluble IgG aggregates.
Doekes G; van Es LA; Daha MR
Immunology; 1983 Jun; 49(2):215-22. PubMed ID: 6852866
[TBL] [Abstract][Full Text] [Related]
17. The influence of classical pathway components during alternative pathway--modulated immune complex aggregation: the role of C1 INH.
Gronski P; Bodenbender L; Kanzy EJ; Seiler FR
Behring Inst Mitt; 1984 Nov; (76):29-41. PubMed ID: 6335396
[TBL] [Abstract][Full Text] [Related]
18. Complement-mediated inhibition of immune precipitation. I. Role of the classical and alternative pathways.
Schifferli JA; Woo P; Peters DK
Clin Exp Immunol; 1982 Mar; 47(3):555-62. PubMed ID: 6979442
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of immune precipitation by complement.
Hong K; Takata Y; Sayama K; Kozono H; Takeda J; Nakano Y; Kinoshita T; Inoue K
J Immunol; 1984 Sep; 133(3):1464-70. PubMed ID: 6747294
[TBL] [Abstract][Full Text] [Related]
20. Control of immune complexes by the classical pathway.
Whaley K; Ahmed AE
Behring Inst Mitt; 1989 Jul; (84):111-20. PubMed ID: 2529842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
